Laboratorios Farmaceuticos Rovi, S.A. Stock
Stocks
ROVI
ES0157261019
Pharmaceuticals
OTC Markets Traded|
Market Closed -
BME
11:36:19 2026-09-21 am EDT
|
5-day change | 1st Jan Change | ||
| 58.85 EUR | +2.08% |
|
+2.71% | -7.32% |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
| Market Cap | 3.01B 3.45B 2.83B 2.58B 4.84B 331B 4.85B 33.95B 13.08B 168B 12.97B 12.68B 544B | P/E 2026 * |
19.9x | P/E 2027 * | 17.5x |
|---|---|---|---|---|---|
| Enterprise Value | 3B 3.44B 2.83B 2.57B 4.83B 330B 4.83B 33.85B 13.05B 168B 12.93B 12.64B 542B | EV / Sales 2026 * |
3.88x | EV / Sales 2027 * | 3.29x |
| Free-Float |
31.63% | Yield 2026 * |
1.65% | Yield 2027 * | 1.97% |
| Markets | Quality | ||
|---|---|---|---|
BME
| ROVI | Delayed | |
CBOE
| ROVIe | Real-time | |
|
Tradegate
| 41L | Real-time | |
|
OTC Markets
| LABF.F | Delayed | |
|
Deutsche Boerse AG
| 41L | Delayed | |
|
Berne S.E.
| 41L | End-of-day quote | |
|
Boerse Muenchen
| 41L | Real-time | |
|
CBOE
| 0ILL | Real-time | |
|
Börse Stuttgart
| 41L | Delayed | |
|
Wiener Boerse
| ROVI | End-of-day quote | |
|
Borsa Italiana
| 1ROVI | End-of-day quote |
Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.
| Jul. 23 | Spanish stocks - Factors to watch on July 23 | RE |
| Feb. 25 | Spanish stocks - Factors to watch on Feb 25 | RE |
| Nov. 06 | Spanish stocks - Factors to watch on Nov 6 | RE |
| 25-03-05 | Spanish stocks - Factors to watch on March 5 | RE |
| 1 day | +2.08% | ||
| 1 week | +2.71% | ||
| Current month | -2.89% | ||
| 1 month | -1.59% | ||
| 3 months | +1.47% | ||
| 6 months | -24.94% | ||
| Current year | -7.32% |
| 1 week | 57.45 |  | 59.4 |
| 1 month | 56.95 | | 62.2 |
| Current year | 53.1 | | 86.7 |
| 1 year | 53.1 | | 86.7 |
| 3 years | 45.52 | | 94.8 |
| 5 years | 35.2 | | 94.8 |
| 10 years | 10.8 | | 94.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2007-07-26 | |
| Director of Finance/CFO | - | 2000-12-31 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 2021-07-16 | |
| Director/Board Member | - | 2007-07-26 | |
| Director/Board Member | - | 2007-07-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/23/23 | Buy | Director | 1,000 | 0.0019% | ||
| 4/13/22 | Norbel Inversiones SL
| Sell | Company | 560,690 | 1.0000% | |
| 3/15/22 | Norbel Inversiones SL
| Sell | Company | 2,803,448 | 5.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.08% | +2.71% | -0.51% | +13.83% | 3.38B | |
| +1.04% | +2.34% | +54.91% | +111.75% | 1,028B | |
| -0.19% | +1.18% | +52.94% | +66.69% | 651B | |
| +0.20% | +1.04% | +18.88% | +72.38% | 466B | |
| +2.24% | +0.94% | +37.61% | +45.31% | 346B | |
| +0.90% | +1.95% | +18.79% | +25.27% | 266B | |
| +0.48% | +3.34% | +11.11% | +15.38% | 259B | |
| +1.95% | +3.06% | +37.75% | +45.93% | 208B | |
| -7.65% | -7.28% | -33.09% | -59.52% | 191B | |
| +0.30% | +2.83% | +31.97% | +100.03% | 186B | |
| Average | +0.23% | +2.47% | +23.04% | +43.70% | 360.51B | |
| Weighted average by Cap. | +0.56% | +2.23% | +35.53% | +65.26% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 774M 888M 729M 664M 1.24B 85.05B 1.25B 8.73B 3.37B 43.33B 3.33B 3.26B 140B | 892M 1.02B 841M 765M 1.44B 98.06B 1.44B 10.07B 3.88B 49.95B 3.84B 3.76B 161B |
| Net income | 146M 168M 138M 125M 235M 16.07B 235M 1.65B 636M 8.19B 630M 616M 26.42B | 173M 198M 163M 148M 278M 19B 278M 1.95B 752M 9.68B 745M 728M 31.23B |
| Net Debt | -8.5M -9.75M -8.01M -7.29M -13.67M -934M -13.69M -95.87M -36.95M -476M -36.62M -35.81M -1.54B | -72.51M -83.16M -68.29M -62.19M -117M -7.97B -117M -818M -315M -4.06B -312M -305M -13.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-21 | €58.85 | +2.08% | 80,702 |
| 26-09-18 | €57.65 | -1.71% | 98,680 |
| 26-09-17 | €58.65 | +0.69% | 64,260 |
| 26-09-16 | €58.25 | +0.69% | 89,314 |
| 26-09-15 | €57.85 | +0.96% | 80,134 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
